key: cord-1045683-yia8bget
authors: Wei, W.; Murdock, D.; Jalbert, J. J.; Mastey, V.; Sanchez, R. J.; Hirshberg, B.; Weinreich, D. M.; Hussein, M.
title: Real-world Effectiveness of Casirivimab and Imdevimab in Patients With COVID-19 in the Ambulatory Setting: An Analysis of Two Large US National Claims Databases
date: 2022-02-28
journal: nan
DOI: 10.1101/2022.02.28.22270796
sha: 049f0126ff769eab5e9976475b4e81280ff62411
doc_id: 1045683
cord_uid: yia8bget

Background: In a phase III clinical trial, casirivimab and imdevimab (CAS+IMD) reduced the composite risk of COVID-19-related hospitalizations or all-cause mortality in outpatients at risk of severe disease. This study assessed the real-world effectiveness of CAS+IMD. Methods: Data from Optum Clinformatics Data Mart (CDM) and IQVIA Pharmetrics Plus (PMTX+) were used to identify patients diagnosed with COVID-19 in ambulatory settings between December 2020 and March 2021 (PMTX+) and June 2021 (CDM), and either treated with CAS+IMD or untreated but treatment-eligible under Emergency Use Authorization. CAS+IMD-treated patients were matched to untreated patients and followed up to 30 days for the composite of all-cause mortality or COVID-19-related hospitalizations (CDM) and COVID-19-related hospitalizations (PMTX+). Kaplan-Meier estimators were used to calculate outcome risks; Cox proportional-hazard models provided adjusted hazard ratios (aHR) with 95% confidence intervals (CI). Results: For CDM, 1116 CAS+IMD-treated patients were matched to 5294 untreated patients; for PMTX+, 3280 CAS+IMD-treated patients were matched to 16 284 untreated patients. The 30-day composite risk was 2.1% and 5.3% in the treated and untreated cohorts, respectively (CDM), and the 30-day risk of COVID-19-related hospitalization was 1.9% and 4.8%, respectively (PMTX+), translating to a 61% lower risk of hospitalization or mortality with CAS+IMD: CDM aHR 0.39 (95% CI 0.26-0.60), PMTX+ aHR 0.39 (95% CI 0.30-0.51). The benefit of treatment was maintained across subgroups, and earlier intervention was associated with improved outcomes. Conclusions: Results of this real-world study further support randomized clinical trial findings that treatment with CAS+IMD reduces the risk of hospitalization and mortality.

In a clinical trial, intravenous casirivimab and imdevimab (CAS+IMD; REGEN-COV ® ) was shown to reduce all-cause mortality or COVID-19-related hospitalization by 71% among patients with mild-to-moderate disease diagnosed and treated in the ambulatory setting [1] . In November 2020, the combination therapy was authorized under an Emergency Use Authorization (EUA) in the US for the treatment of mild-tomoderate COVID-19 patients who are at risk for severe disease [2] . In June 2021, the subcutaneous administration of CAS+IMD received EUA as an alternative when intravenous infusion is not feasible and would delay treatment. In January 2022, the FDA amended the EUA of CAS+IMD to exclude its use in geographic regions where, based on available information including variant susceptibility and regional variant frequency, infection or exposure is likely due to a variant such as Omicron (B.1.1.529); because of markedly reduced neutralization activity, CAS+IMD is not expected to be active against Omicron [3] .

While multiple studies have reported on the real-world effectiveness of CAS+IMD 5 assess the effectiveness of CAS+IMD in subgroups of patients at higher risk of poor outcomes are needed. The objective of this study was to compare the effectiveness of CAS+IMD versus no COVID-19 mAb treatment on 30-day all-cause mortality or COVID-19-related hospitalization among patients diagnosed with COVID-19 in the ambulatory setting overall and among subgroups of patients at high-risk of poor COVID-19 outcomes.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ; https://doi.org/10.1101/2022.02.28.22270796 doi: medRxiv preprint

This retrospective cohort study was conducted in the US using data from the Optum Clinformatics Data Mart (CDM) and the IQVIA Pharmetrics Plus (PMTX+) databases.

Since both databases contain de-identified data and are fully compliant with the Health Insurance Portability and Accountability Act, institutional review board/ethics committee approval was not required. Study design and statistical analyses were described and specified a priori in a study protocol.

The CDM database contains administrative health claims for 68 million members with month-by-month information on enrolled patients. However, in contrast to CDM, information was not available on mortality during the study period.

Patients with either a COVID-19 diagnosis (International Classification of Diseases were eligible for inclusion. Patients who were hospitalized as a result of the encounter . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ; https://doi.org/10.1101/2022.02.28.22270796 doi: medRxiv preprint were excluded. Among eligible patients, we identified those who received CAS+IMD (date of treatment was defined as the index date) and a group of patients who were not treated with any COVID-19 mAb but were eligible to receive CAS+IMD under the EUA.

These untreated patients were assigned a random index date drawn from the distribution between days from COVID-19 diagnosis and treatment for CAS+IMDtreated patients. Additional inclusion criteria were continuous healthcare plan enrollment for at least 6 months pre-index (ie, baseline period); ≥ 12 years of age at index; and diagnosis for COVID-19 or positive test in the 10 days prior to or on the index date (days 0 to -10) but no diagnosis in the previous 30-day period (days -11 to -40) in order to capture the first manifestation of COVID-19 infection rather than complication or follow-up care from a previous episode; and have a valid date of death (CDM only).

Patients were excluded if they received COVID-19 mAbs during baseline or multiple COVID-19 mAbs on the index date; or died or were hospitalized between the COVID-19 diagnosis and the index date, inclusive.

Outcomes were the composite endpoint 30-day all-cause mortality or COVID-19-related hospitalizations for CDM, and 30-day COVID-19-related hospitalizations for PMTX+. A COVID-19-related-hospitalization was defined as hospitalization with a COVID-19 diagnosis as the primary or admitting diagnosis. In CDM, mortality information is derived from the Centers for Medicare and Medicaid Services (CMS), the Social Security Administration (SSA) Death Master File, facility claims indicating that the patient was deceased when discharged, and member coverage information stating the reason for coverage discontinuation was death. PMTX+ does not contain patient mortality data.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) and COVID-19 vaccination status identified using ICD-10 codes. The Charlson Comorbidity Index (CCI) score [17] was determined using ICD-10 diagnosis codes to identify the presence of CCI comorbidities during the baseline period. We also used ICD-10 codes to identify body mass index (BMI), categorized as normal, overweight, obese, severely/morbidly obese; comorbid conditions such as cardiovascular disease (myocardial infarction, hypertension, atrial fibrillation, heart failure, ischemic/hemorrhagic stroke, or venous thromboembolism), chronic respiratory disease (asthma, chronic obstructive pulmonary disease, obstructive sleep apnea, pulmonary fibrosis, cystic fibrosis), cancer, and diabetes (type 1 or 2). Hospitalizations or emergency room/urgent care visits during the baseline period were also captured.

Risk factors based on EUA criteria at the time of the initial CAS+IMD authorization were identified using ICD-10 diagnosis codes, procedure codes, and drug dispensation/administration codes over the baseline period. 

To control for confounding, untreated EUA-eligible patients were matched to those treated with CAS+IMD without replacement, using exact and probabilistic methods.

Propensity score (PS) models predicting the probability of CAS+IMD versus no treatment were derived by including demographic characteristics, individual EUA criteria, CCI score, baseline period hospitalization, days from diagnosis to index date, and emergency room as the ambulatory setting of the diagnosis. CAS+IMD-treated patients were then matched to up to 5 EUA-eligible untreated patients on state, index month, BMI group, and within a caliper width of 0.02 of the PS scale. A variable matching ratio was used to balance between minimizing bias and maximizing the matched sample size to strengthen the statistical power and improve generalizability [20] . Standardized mean differences (SMD) were used to assess balance between treatment groups; SMD >10 indicates imbalance.

Descriptive analyses of baseline characteristics included means and medians with their standard deviations and interquartile ranges, respectively, for continuous variables, and . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Table 1 ). To investigate the effect of delayed treatment among patients treated with CAS+IMD, outcomes were stratified by days from initial COVID-19 diagnosis to treatment: 1 day, 2 days, 3-4 days, and ≥ 5 days. The 30-day outcome risks were estimated for each subgroup using KM estimators, and Cox proportionalhazards models were used to derive aHRs by sub-setting to the subgroup of interest and fitting the model to matched pairs. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 28, 2022.

No adjustments were made for multiple comparisons; all P-values are nominal with significance set at α = .05.

Sensitivity analyses included changing the definition of a COVID-19-related hospitalization to a hospitalization with a confirmed COVID-19 diagnosis in the primary position only; changing the definition of a COVID-19-related hospitalization to a hospitalization with a confirmed COVID diagnosis in any position; requiring that treated patients be treated within 7 days of a COVID-19 diagnosis; requiring that the EUA criteria be met for both cohorts; and removal of the COVID-19 diagnosis setting from the propensity score.

The analytic file was created, and all analyses were conducted using Instant Health Data platform (Panalgo, Boston, MA, USA).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ;

In the CDM database, before matching, we identified 1167 patients diagnosed with COVID-19 in ambulatory settings who were treated with CAS+IMD and met all other inclusion criteria and 178 240 untreated EUA-eligible patients ( Figure 1A and Supplementary Table 2 ). Of these, 1116 CAS+IMD-treated patients were matched with 5291 of the untreated patients. Demographic characteristics of the matched cohort showed that the treated and untreated groups were primarily Caucasian (~70%), ~52%

were males, mean age ± standard deviation was 53.0 ± 12.6 and 54.1 ± 12.6 years, respectively, and the greatest representation was from the Southern US (54.4% and 54.8%, respectively) ( Table 1 and Supplementary Table 3 ).

In the PMTX+ database, 3284 CAS+IMD-treated patients and 270 553 untreated EUA-eligible patients were identified before matching (Figure 1B and Supplementary   Table 2 ); 3280 CAS+IMD-treated patients were matched to 16 284 untreated patients.

Baseline characteristics were generally similar to the CDM database ( Table 1 and   Supplementary Table 3 ).

The SMDs showed that, overall, matched patients in each dataset were wellbalanced (except for time from diagnosis) ( Table 1) . Additionally, patients in CDM and PMTX+ databases were generally similar except for different regional distribution, index month, location of COVID-19 diagnosis, and vaccination status.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ;

Among those treated with CAS+IMD, the mean and median times from diagnosis to index date showed a generally short duration between diagnosis and treatment (≤3 days) ( Table 1) . The prevalence of COVID-19 risk factors was similar between treated patients in the CDM and PMTX+ databases; cardiovascular disease or hypertension had the highest prevalence, 53.0%-59.0%, followed by diabetes, 28.5%-33.4%, respectively ( Table 1 ). In CDM and PMTX+, 12.9%-15.6% of patients were ≥ 65 years of age, and 18.1%-23.3% had an obesity-related diagnosis ( Table 1) .

In CDM, event rates for the composite endpoint of 30-day post-index all-cause mortality/COVID-19-related hospitalizations were 2.1% (95% CI 1. Treatment with CAS+IMD was associated with a 61% lower risk when compared to the untreated EUA-eligible patients for the composite endpoint (aHR 0.39, 95% CI 0.26-0.60; Figure 3A ) in the CDM population and for COVID-19-related hospitalizations . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ;

(aHR 0.39, 95% CI 0.30-0.51; Figure 3B ) in the PTMX+ population. Results were robust across sensitivity analyses (Figure 3 ).

Compared to the untreated group, CAS+IMD treatment was associated with a consistently lower risk (28%-88%) of the outcomes across subgroups in both databases ( Figure 4) . The largest effect sizes were observed in patients with cancer/receiving chemotherapy (66% and 75% in CDM and PMTX+, respectively) and B-cell deficiencies (88% and 66% in CDM and PMTX+, respectively). In CDM, the estimate did not reach statistical significance within a few subgroups with small sample sizes in the treated group, including those >64 years of age, >3 EUA risk factors, and those with cancer/receiving chemotherapy). . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ;

This retrospective cohort study suggests that in non-hospitalized patients diagnosed with COVID-19, treatment with CAS+IMD was associated with a significantly lower risk of subsequent 30-day all-cause mortality or COVID-19-related hospitalization relative to no mAb treatment when the variant is susceptible to neutralization by the therapy.

These effects were even more pronounced among patients at elevated risk and those with B-cell deficiencies. Furthermore, these findings were consistent across two large independent databases, affirming the robustness of observed effectiveness of CAS+IMD treatment. These results further support the significant reduction in risk of allcause mortality or COVID-19 related hospitalization that was previously reported with CAS+IMD in the phase III clinical trial [1] .

Evidence from several real-world studies suggests that appropriate treatment with CAS+IMD was associated with an incidence of hospitalizations that may be 50%-90% lower than among untreated patients [4, 5, 8, 9, 16, 23] . The magnitude of effects observed in the current study fell within that range and, additionally, demonstrated greater benefits among those at higher risk. However, it should be noted that there was substantial heterogeneity in populations and outcomes among the real-world studies, including use of a shorter follow-up [9] or more broadly defined endpoints such as allcause hospitalizations [4, 9, 23] or medically attended visits (ie, hospitalizations and emergency department) [13] .

Importantly, treatment with CAS+IMD appeared to have a benefit on mortality in the CDM cohort, as the 30-day estimated risk of death was much lower in the treated . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ; than untreated patients. These results further support the public health implications of this therapy, and are consistent with the real-world studies that also suggested lower mortality in patients who received mAb treatment [9, 11, 15, 16], albeit in variants susceptible to such therapy.

The current study also expands on the results of the clinical trial and real-world studies by demonstrating that treatment with CAS+IMD may be especially beneficial for improving outcomes in subgroups of patients at higher risk of severe disease. Among these subgroups are those who are immunocompromised such as patients with a variety of B-cell deficiencies, or those defined as having an elevated risk (ie, The results show a clear association between timing of treatment and therapeutic benefit, emphasizing that patients should be treated as soon as possible to receive the maximal benefit of treatment. These results also highlight the need for rapid outpatient diagnosis and subsequent early initiation of treatment for those who meet the EUA criteria.

Potential limitations of this analysis include that claims data do not capture COVID-19 disease severity (eg, viral load) or symptom data, including time of symptom onset, which are important predictors of hospitalization and mortality and may be used by clinicians to inform treatment decisions. Since the study was non-randomized, this limitation may result in residual confounding due to channeling bias; some patients may not have been treated because they may have had milder disease than those who were . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ; treated, potentially leading to underestimation of CAS+IMD effectiveness. Potentially important confounders such as BMI and COVID-19 vaccination are not well captured in claims data; assuming patients with higher BMI and those who are unvaccinated would be more likely to have worse disease and be treated, residual confounding would likely bias results against CAS+IMD. Misclassification may similarly result from use of days from diagnosis to treatment as a proxy for the duration from symptom onset to treatment as, for many patients, COVID-19 symptoms are likely to have started prior to diagnosis.

Furthermore, the data were sourced at a time when vaccinations were not routinely available, particularly in the PMTX+ database, thus limiting the generalizability of our findings. Additionally, the current findings may not be generalizable to future variants, such as Omicron, where laboratory studies have found markedly reduced neutralization activity [24, 25] . Finally, the claims data were not able to distinguish between subcutaneous and intravenous formulations of CAS+IMD. Despite these limitations, the design and methods employed in this study, as well as, the robustness of results observed in the sensitivity analyses provide a degree of confidence with the results.

In conclusion, results from this real-world study are consistent with and extend those observed in the randomized clinical trials. This study demonstrated that, relative to untreated EUA-eligible patients, in an environment where the variant is known to be neutralized by CAS+IMD, treatment was associated with a significant 61% reduction in is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ; benefit from treatment, such as those who are immunocompromised (ie, cancer/chemotherapy or B-cell deficiencies) and those at elevated risk. CAS+IMD was also associated with a low absolute event rate, but these rates increased with delayed treatment, suggesting the importance of early diagnosis and treatment in the ambulatory setting.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ;

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ; is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. .

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ;

Diagnosed with or tested positive for COVID-19 during the study period (n=566 755)

Received CAS+IMD during the study period (n=1588)

Had COVID-19 diagnosis or positive tests within 10 days prior to or on treatment date but not within 11-40 days prior (n=1450) Matched to the treatment group (n=5291)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ;

Abbreviations: CAS+IMD, casirivimab and imdevimab; COVID-19, coronavirus disease 2019; EUA, Emergency Use Authorization; mAb, monoclonal antibody. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. .

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. .

It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 28, 2022. 

REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19

Food & Drug Administration. Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Casirivimab and Imdevimab. Revised

COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant

COVID-19 Patients Treated with Monoclonal Antibody Therapy: A Propensity Score-Matched Cohort Study

Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities

Real-World Clinical Outcomes of